AbbVie Joins BCMA Race with Tenebio in a US$90 M Upfront Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 14 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2406     ISSN: 1756-7874

Section: Licensing



In its first venture into the B-cell maturation antigen (BCMA) space, AbbVie has entered into a global agreement with Teneobio and its affiliate, TeneoOne, to develop and commercialise TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details